Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Cash from Investing Activities: 2009-2024

Historic Cash from Investing Activities for Cumberland Pharmaceuticals (CPIX) over the last 16 years, with Dec 2024 value amounting to $57,842.

  • Cumberland Pharmaceuticals' Cash from Investing Activities fell 464.29% to -$690,837 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 million, marking a year-over-year decrease of 580.75%. This contributed to the annual value of $57,842 for FY2024, which is 154.73% up from last year.
  • As of FY2024, Cumberland Pharmaceuticals' Cash from Investing Activities stood at $57,842, which was up 154.73% from -$105,695 recorded in FY2023.
  • In the past 5 years, Cumberland Pharmaceuticals' Cash from Investing Activities ranged from a high of $57,842 in FY2024 and a low of -$13.7 million during FY2022.
  • For the 3-year period, Cumberland Pharmaceuticals' Cash from Investing Activities averaged around -$4.6 million, with its median value being -$105,695 (2023).
  • As far as peak fluctuations go, Cumberland Pharmaceuticals' Cash from Investing Activities crashed by 2,624.58% in 2022, and later skyrocketed by 154.73% in 2024.
  • Over the past 5 years, Cumberland Pharmaceuticals' Cash from Investing Activities (Yearly) stood at -$1.8 million in 2020, then spiked by 71.45% to -$501,893 in 2021, then plummeted by 2,624.58% to -$13.7 million in 2022, then skyrocketed by 99.23% to -$105,695 in 2023, then surged by 154.73% to $57,842 in 2024.